Conference Coverage

Coverage from professional conferences on research relevant to pancreatic cancer.
Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer
Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% ..
Feasibility and First Clinical Results of Hypofractionated Scanning Proton-Beam Therapy for Inoperable Pancreatic Cancer
Presenting Author: A. Haidenberger MD Presenting Author Affiliation: Rinecker Proton Therapy Center, Munich Background Pancreatic cancer is an aggressive malignancy, with median survival of 5-8 months after diagnosis. The standard ..
A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial
Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative ..
Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study
Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the ..
A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12
Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year ..
Simultaneous Gemcitabine/Cisplatin and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma using a Strict GEM/RT Time Schedule. A Phase I/II Study
Presenter: T. Brunner Presenter's Affiliation: University Hospitals Erlangen, Erlangen, Germany Type of Session: Scientific Background Patients with locally advanced pancreatic cancer treated with induction chemoradiation (CRT) prior to surgery have ..
Gemcitabine, Paclitaxel, and Radiation for Locally Advanced Pancreatic Cancer: A Phase I Trial
Presenter: T. Dipetrillo Presenter's Affiliation: Brown University Type of Session: Scientific Background Locally advanced pancreatic cancer has Gemcitabine and paclitaxel are both radiation sensitizers The use of paclitaxel has demonstrated ..
Initial Results Of Preoperative Gemcitabine (GEM)-Based Chemoradiation For Resectable Pancreatic Adenocarcinoma
Presenter: Robert A WolffPresenter's Affiliation: UT MD Anderson Cancer Ctr, Houston, TXType of Session: ScientificBackground The recurrence rate in patients with adenocarcinoma of the pancreas following pancreaticoduodenectomy with curative intent ..
Gemcitabine vs. GEMOX (gemcitabine + oxaliplatin) in non-resectable pancreatic adenocarcinoma: Interim results of GERCOR/GISCAD intergroup Phase III
Presenter: C. LouvetPresenter's Affiliation: Hospital St. Antoine; Paris, FranceType of Session: ScientificBackground Gemcitabine 1g/m2 in a 30 min infusion remains the reference regimen for non-resectable pancreatic cancer. Oxaliplatin and Gemcitabine ..
A Phase III Trial comparing Gemcitabine plus Cisplatin vs. Gemcitabine alone in advanced pancreatic cancer
Presenter: V. HeinemannPresenter's Affiliation: University of Munich; Munich, GermanyType of Session: ScientificBackground Pancreatic cancer has a very poor prognosis. Most patients are diagnosed in the metastatic stage. Median survival is ..
Recent Clinical Advances in Pancreatic Cancer
Conference Dates: September 28, 2005, 6:00pm Conference Location: Riva, 700 E. Grand Avenue/Navy Pier, Chicago, IL 60611 Sponsoring Group: The CBCE Conference Web Page URL: www.thecbce.com/futureprograms.asp Who Should Attend: MDs ..
Adjuvant Multimodality with Gemcitabine versus 5-Fluorouracil in Pancreatic Cancer: Status of U.S. Intergroup Trial
Faculty Disclosure: William F. Regine, M.D. Nothing to Disclose Presenter: William F. Regine, M.D. Affiliation: University of Maryland Even with potentially curative resection, 5 year survival for pancreatic cancer patients ..
Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer.  A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG)
Presenter: M.J. MoorePresenter's Affiliation: NCICType of Session: PlenaryBackground Advanced and metastatic pancreatic cancer has an extremely poor prognosis, with median survival times between 4-6 months. Multiple attempts at combination chemotherapy ..
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma.
Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after chemotherapy and ..
Gemcitabine and Erlotinib in Pancreatic Cancer
Presenter: Malcolm Moore, MDPresenter's Affiliation: Princess Margaret HospitalType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer-related deaths. In 2005, there will be an estimated 35,400 new ..
Pancreatic Cancer: Progress on the Horizon
Presented by: Shannon Holloway, MHS , PA -C, New York Presbyterian Weill Cornell Medical Center Pancreatic cancer accounts for 30,500 new cases annually, with a dismal 5-year survival rate of ..
RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma
Presenter: William F. ReginePresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Adenocarcinoma of the pancreas, even when resectable, has a poor prognosis.  Failures occur both locoregionally and systemically. ..
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma
Presenter: Abrams, R et al.Presenter's Affiliation: University of Maryland School of MedicineType of Session: ScientificBackground Pancreatic cancer is a very difficult cancer to treat and cure A previously published phase ..
A Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Post-chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcionma
Intra-arterial vs. Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial Locally advanced squamous cell head and neck cancer is often treated with a combination ..
A Double-Blind, Placebo Controlled, Randomized Phase III trial of Gemcitabine (G) plus Bevacizumab (B) Versus Gemcitabine Plus Placebo (P) in Patients (pts) with Advanced Pancreatic Cancer (PC): A Preliminary Analysis of Cancer and Leukemia Group B (CALGB)
Presenter: H. L. KindlerPresenter's Affiliation: University of Chicago Medical CenterType of Session: ScientificBackground Advanced pancreatic cancer continues to have an extremely poor prognosis. Gemcitabine is the cornerstone of treatment and ..
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer
Scientific Session: Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced ..
Post-resectional CA 19-9 Values >90 are Associated With Significantly Worse Survival in Patients With Pancreatic Carcinoma Treated With Adjuvant Therapy on RTOG 9704 - Implications for Current and Future Trials
Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Radiation Therapy Oncology GroupType of Session: ScientificBackground The CONKO-001 phase III trial (Oettle H, et al. JAMA. 2007;297(3):267-77) recently ..
Characterization of Pancreatic Tumor Motion Using 4D MRI: Surrogates for Tumor Position Should be Used With Caution
Presenter: Mary Feng, MDPresenter's Affiliation: University of Michigan Medical CenterType of Session: PlenaryBackground Pancreatic cancer is associated with poor outcomes and limited long-term survival, and there are numerous challenges that ..
Definitive Results of the French FFCE-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplating and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients with Locally Advanced Non Metastatic Pancreatic Cancer
Presenter: C.H. Crane substituting for F. MornexPresenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon Pierre Benite, FranceType of Session: ScientificBackground Pancreatic cancer is the fourth most common malignancy in the United ..
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon
Presenter: Picozzi R.A.Presenter's Affiliation: Virginia Mason Medical Center, Seattle WashingtonType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States and in 2007, ..
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC)
Presenter: Neumann J.P.Presenter's Affiliation: Charite School of Medicine, Berlin, GermanyType of Session: ScientificBackground Pancreatic cancer is the fourth leading cause of cancer death in the United States, and in 2007, ..
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon
ACOSG ZO531: Report on a Multicenter, Phase II Trial for Adjuvant Therapy of Resected Pancreatic Cancer Using Cisplatin, 5-FU, and Alpha-Interferon Surgery is considered the only curative therapy for pancreatic ..
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC)
CONKO-001: Final Results of the Randomized, Prospective, Multicenter Phase III Trial of Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients with Resected Pancreatic Cancer (PC) This study has previously reported ..
A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201
A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer: E4201 Prior studies of gemcitabine with radiation therapy ..
Postoperative Adjuvant Gemcitabine Plus Oxaliplatin (GemOx)Chemotherapy in Patients with Pancreatic Adenocarcinoma: Final Results of a Single Arm Multicenter Phase II Study
Presenter: Francoise Mornex Presenter's Affiliation: Centre Hospitalier Lyon Sud, Lyon, France Type of Session: Scientific Background Pancreas cancer treated with surgery alone has produced disappointing results including high rates of ..
Comparison of Proton and Photon Radiation Treatment Plans for the Adjuvant Treatment of Pancreatic Cancer Including Comprehensive Nodal Radiation
Presenter: Mark Ingram Presenter's Affiliation: University of Pennsylvania Type of Session: Poster Background Pancreatic cancer is the fourth leading cause of death and most patients present with unresectable disease. The ..
Use of endoscopic ultrasonography in screening patients at high-risk for pancreatic cancer
Presenter: J. Poley, University Medical Center, Rotterdam, Netherlands Background Screening of the general population for certain malignancies, including breast cancer, prostate cancer, colon cancer, and cervix cancer has become standard ..
First Report of Real-time Tumor Tracking in the Treatment of Pancreatic Cancer using the Calypso System
Presenter: James M. Metz, MDPresenter's Affiliation: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PAType of Session: ScientificBackground In the United States, surgery followed by combined modality therapy with ..
Five-year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Postchemoradiation (CRT) 5-FU vs. Gemcitabine (G) For Resected Pancreatic Adenocarcinoma: Implications for Future International Trial Design
Presenter: William F. Regine, MDPresenter's Affiliation: University of Maryland Medical Center, Baltimore, MDType of Session: ScientificBackground Due to the often advanced stage of presentation among patients with pancreatic adenocarcinoma, only ..
Understanding Pancreatic Cancer: A Free Educational Lecture
Dates: October 15, 2011 Location: Cancer Support Community of Philadelphia, The Suzanne Morgan Center at Ridgeland, 4100 Chamounix Dr., Phila. PA 19131 Sponsoring Group: Pancreatic Cancer Action Network and the ..
Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates
Presenter: Daniel D. Von Hoff, MD Presenter's Affiliation: Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare/TGen, Scottsdale, Abstract #: 4005 Background Metastatic pancreatic cancer is a lethal disease ..


I Wish You Knew

Pancreatic Cancer & Family History

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More



OncoLink Cancer Treatment and Resources